Baek and colleagues found that the inhibition of tumor development in individuals with DS may be due in part to the suppression of tumor angiogenesis, specifically the increased expression of DS candidate region 1 (Dscr1, RCAN1), which encodes a protein that suppresses vascular endothelial growth factor (VEGF)-mediated angiogenic signaling via the calcineurin pathway [36,37,38,39]. Here, VEGFA is linked to neoplasm.